MSD: Catheter, Hemodialysis, Implanted

Product code MSD, “Catheter, Hemodialysis, Implanted” in FDA's classification database, is a Class II device type under 21 CFR 876.5540 (blood access device and accessories), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 124 clearances under MSD, 39 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
MSD
Regulation
21 CFR 876.5540
Class
II
Panel
Gastroenterology, Urology
Clearances
124
Most recent
May 16, 2025
Median review, last 2 years
347 days
Third-party review
Not eligible
Implant
Yes

What it covers

A blood access device and accessories is a device intended to provide access to a patient's blood for hemodialysis or other chronic uses. When used in hemodialysis, it is part of an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and provides access to a patient's blood for hemodialysis. The device includes implanted blood access devices, nonimplanted blood access devices, and accessories for both the implanted and nonimplanted blood access devices.

(1) The implanted blood access device is a prescription device and consists of various flexible or rigid tubes, such as catheters, or cannulae, which are surgically implanted in appropriate blood vessels, may come through the skin, and are intended to remain in the body for 30 days or more. This generic type of device includes various catheters, shunts, and connectors specifically designed to provide access to blood. Examples include single and double lumen catheters with cuff(s), fully subcutaneous port-catheter systems, and A-V shunt cannulae (with vessel tips). The implanted blood access device may also contain coatings or additives which may provide additional functionality to the device.

(2) The nonimplanted blood access device consists of various flexible or rigid tubes, such as catheters, cannulae or hollow needles, which are inserted into appropriate blood vessels or a vascular graft prosthesis (§§ 870.3450 and 870.3460), and are intended to remain in the body for less than 30 days. This generic type of device includes fistula needles, the single needle dialysis set (coaxial flow needle), and the single needle dialysis set (alternating flow needle).

(3) Accessories common to either type include the shunt adaptor, cannula clamp, shunt connector, shunt stabilizer, vessel dilator, disconnect forceps, shunt guard, crimp plier, tube plier, crimp ring, joint ring, fistula adaptor, and declotting tray (including contents).

The identification in 21 CFR 876.5540, blood access device and accessories. FDA gives MSD no definition of its own, so the regulation’s describes it.

FDA flags MSD devices as implants and life-sustaining or life-supporting.

Recent clearances

510(k)DeviceApplicantDecisionType
K241581Hemodialysis CatheterHaolang Medical USA CorporationMay 16, 2025Traditional
K210461End CapMedical Components Inc (Medcomp)Sep 14, 2021Traditional
K203575GlidePath Retro Long-Term Hemodialysis CatheterC.R. Bard, Inc.Jul 1, 2021Traditional
K211410GlidePath 13F Long-Term Hemodialysis CatheterBard Peripheral Vascular, Inc.Jun 4, 2021Special
K203767Pristine Long-Term Hemodialysis CatheterC B Bard, Inc.Apr 2, 2021Traditional
K202150GlidePath 7.5F Long-Term Dialysis CatheterC.R. Bard, Inc.Nov 18, 2020Traditional
K202176Symetrex LTHD Catheter, Symetrex LTHD Catheter with SideholesMedical Components, Inc. (dba MedComp)Sep 3, 2020Special
K200627GlidePath 10F Long-Term Dialysis CatheterC.R. Bard, Inc.Jun 22, 2020Traditional
K190527GlidePath Long-Term Hemodialysis Catheters, HemoStar Long-Term Hemodialysis Catheters, HemoStar XK Long-Term Hemodialysis CathetersC. R. BardMar 5, 2020Traditional
K182443Pristine Hemodialysis CatheterPristine Access Technologies , Ltd.May 31, 2019Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 124 with a free account)

Clearances by year

39 MSD 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
20251347
20214153
20204106
20191266
20182112
20172176
20162191
20151105
20148246
20135105
2012298
2011770

Who submits

21 applicants cleared a MSD device since 2011. 87% of the clearances went to applicants in United States, then Ireland (10%) and Israel (3%). By type: Traditional 67% and Special 33%.

ApplicantClearances since 2011
Marvao Medical Devices, Ltd.7
C.R. Bard, Inc.3
Covidien3
Medical Components, Inc.3
Teleflexmedical, Inc.3
Ameco Medical Industries2
Arrow International, Inc.2
Medical Components, Inc. (dba MedComp)2

How FDA classifies it

(1) Class II (special controls) for the implanted blood access device. The special controls for this device are:

(i) Components of the device that come into human contact must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided.

(ii) Performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:

(A) Pressure versus flow rates for both arterial and venous lumens, from the minimum flow rate to the maximum flow rate in 100 milliliter per minute increments, must be established. The fluid and its viscosity used during testing must be stated.

(B) Recirculation rates for both forward and reverse flow configurations must be established, along with the protocol used to perform the assay, which must be provided.

(C) Priming volumes must be established.

(D) Tensile testing of joints and materials must be conducted. The minimum acceptance criteria must be adequate for its intended use.

(E) Air leakage testing and liquid leakage testing must be conducted.

(F) Testing of the repeated clamping of the extensions of the catheter that simulates use over the life of the device must be conducted, and retested for leakage.

(G) Mechanical hemolysis testing must be conducted for new or altered device designs that affect the blood flow pattern.

(H) Chemical tolerance of the device to repeated exposure to commonly used disinfection agents must be established.

(iii) Performance data must demonstrate the sterility of the device.

(iv) Performance data must support the shelf life of the device for continued sterility, package integrity, and functionality over the requested shelf life that must include tensile, repeated clamping, and leakage testing.

(v) Labeling of implanted blood access devices for hemodialysis must include the following:

(A) Labeling must provide arterial and venous pressure versus flow rates, either in tabular or graphical format. The fluid and its viscosity used during testing must be stated.

(B) Labeling must specify the forward and reverse recirculation rates.

(C) Labeling must provide the arterial and venous priming volumes.

(D) Labeling must specify an expiration date.

(E) Labeling must identify any disinfecting agents that cannot be used to clean any components of the device.

(F) Any contraindicated disinfecting agents due to material incompatibility must be identified by printing a warning on the catheter. Alternatively, contraindicated disinfecting agents must be identified by a label affixed to the patient's medical record and with written instructions provided directly to the patient.

(G) Labeling must include a patient implant card.

(H) The labeling must contain comprehensive instructions for the following:

(1) Preparation and insertion of the device, including recommended site of insertion, method of insertion, and a reference on the proper location for tip placement;

(2) Proper care and maintenance of the device and device exit site;

(3) Removal of the device;

(4) Anticoagulation;

(5) Management of obstruction and thrombus formation; and

(6) Qualifications for clinical providers performing the insertion, maintenance, and removal of the devices.

(vi) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices that include subcutaneous ports must include the following:

(A) Labeling must include the recommended type of needle for access as well as detailed instructions for care and maintenance of the port, subcutaneous pocket, and skin overlying the port.

(B) Performance testing must include results on repeated use of the ports that simulates use over the intended life of the device.

(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.

(vii) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices with coatings or additives must include the following:

(A) A description and material characterization of the coating or additive material, the purpose of the coating or additive, duration of effectiveness, and how and where the coating is applied.

(B) An identification in the labeling of any coatings or additives and a summary of the results of performance testing for any coating or material with special characteristics, such as decreased thrombus formation or antimicrobial properties.

(C) A Warning Statement in the labeling for potential allergic reactions including anaphylaxis if the coating or additive contains known allergens.

(D) Performance data must demonstrate efficacy of the coating or additive and the duration of effectiveness.

(viii) The following must be included for A-V shunt cannulae (with vessel tips):

(A) The device must comply with Special Controls in paragraphs (b)(1)(i) through (v) of this section with the exception of paragraphs (b)(1)(ii)(B), (b)(1)(ii)(C), (b)(1)(v)(B), and (b)(1)(v)(C), which do not apply.

(B) Labeling must include Warning Statements to address the potential for vascular access steal syndrome, arterial stenosis, arterial thrombosis, and hemorrhage including exsanguination given that the device accesses the arterial circulation.

(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.

(2) Class II (performance standards) for the nonimplanted blood access device.

(3) Class II (performance standards) for accessories for both the implanted and the nonimplanted blood access devices not listed in paragraph (b)(4) of this section.

(4) Class I for the cannula clamp, disconnect forceps, crimp plier, tube plier, crimp ring, and joint ring, accessories for both the implanted and nonimplanted blood access device. The devices subject to this paragraph (b)(4) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.

From 21 CFR 876.5540. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 876.5540 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent MSD clearances declared.

Ask about MSD

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about MSD

What is FDA product code MSD?

Product code MSD, “Catheter, Hemodialysis, Implanted” in FDA's classification database, is a Class II device type under 21 CFR 876.5540 (blood access device and accessories), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 124 clearances under MSD, 39 of them since 2011.

How many 510(k) clearances are there under MSD?

FDA’s 510(k) database listed 124 clearances under MSD as of Oct 29, 2026, 39 of them decided since 2011; the most recent decision was May 16, 2025. The Predicate Finder searches the live database.

How long does FDA take to clear a MSD 510(k)?

For the 1 MSD clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 347 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most MSD clearances?

Since 2011: Marvao Medical Devices, Ltd. (7), C.R. Bard, Inc. (3), Covidien (3), Medical Components, Inc. (3) and Teleflexmedical, Inc. (3). 21 applicants have cleared a MSD device in that time.

Sources

  1. FDA product classification: MSD · Product Classification database
  2. 21 CFR 876.5540: Blood access device and accessories · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for MSD · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow MSDGet an email when FDA clears, recalls or publishes guidance for MSD devices.

Know what FDA already cleared.